One year after the ESC/EAS guidelines on cholesterol control. What's the new evidence? What's missing?

This publication has 30 references indexed in Scilit:

• Statin use and risk of new-onset diabetes: A meta-analysis of observational studies
  Nutrition, Metabolism and Cardiovascular Diseases, 2017
• Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel
  European Heart Journal, 2017
• A Highly Durable RNAi Therapeutic Inhibitor of PCSK9
  New England Journal of Medicine, 2017
• Liver-specific ATP-citrate lyase inhibition by bempedoic acid decreases LDL-C and attenuates atherosclerosis
  Nature Communications, 2016
• Interpretation of the evidence for the efficacy and safety of statin therapy
  The Lancet, 2016
• 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
  European Heart Journal, 2016
• Understanding IMPROVE-IT and the cardinal role of LDL-C lowering in CVD prevention
  European Heart Journal, 2014
• Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: Consensus Statement of the European Atherosclerosis Society
  European Heart Journal, 2013
• Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials
  The Lancet, 2010
• Lipoprotein(a) Concentration and the Risk of Coronary Heart Disease, Stroke, and Nonvascular Mortality
  JAMA, 2009